Filing identity and reporting period
Important mismatch: The supplied filing is Synta Pharmaceuticals Corp.’s Form 10-K for the fiscal year ended December 31, 2011, filed February 22, 2012. It is not a filing by Madrigal Pharmaceuticals, Inc., and it is an annual report rather than a standalone Q4 filing. The summary below reflects Synta’s filing.
Business context
Synta was a clinical-stage biopharmaceutical company developing small-molecule medicines, principally for cancer and inflammatory diseases. It had no product sales and relied on financing, grants, and collaboration-related revenue. Its lead candidate was ganetespib; other programs included elesclomol, STA-9584, CRACM inhibitors, and IL-12/23 inhibitors.
Financial results and liquidity
- 2011 revenue: $7.6 million, down 49% from $14.8 million in 2010. Revenue comprised $6.7 million of license and milestone revenue and $0.9 million of grant revenue; there were no cost-sharing reimbursements in 2011.
- Expenses and loss: R&D expense was $41.5 million, up 3%; general and administrative expense was $11.6 million, essentially unchanged. Operating loss was $45.4 million, compared with $36.9 million in 2010. Net loss was $47.4 million, or $1.00 per share, versus $37.5 million, or $0.93 per share, in 2010. The company reported no product revenue, so product-level margins are not applicable.
- Cash flow: Operating activities used $47.3 million, versus $38.2 million in 2010. Investing activities provided $9.3 million and financing activities provided $36.7 million.
- Year-end liquidity: Cash, cash equivalents, and marketable securities totaled $39.7 million at December 31, 2011, down from $51.0 million a year earlier. Working capital was $25.1 million.
- Debt and commitments: Term loans totaled approximately $16.6 million in balance-sheet carrying value, including $4.2 million current and $12.4 million long-term. The GECC loan bore 9.75% interest and the Oxford loan 13.35%. Contractual obligations totaled $41.2 million, including leases, loan payments, and R&D contracts.
- Subsequent financing: A January–February 2012 stock offering raised approximately $33.0 million net. Management said available cash, including those proceeds, was expected to fund operations into the first half of 2013, subject to planned activities and available resources.
Changes versus prior periods
- Revenue fell from 2010 as Roche cost-sharing reimbursements ended; the 2011 total included a one-time $2.1 million acceleration of deferred Roche license revenue after Roche elected to terminate its agreement. The termination became effective February 16, 2012.
- Net loss widened by $9.9 million, reflecting higher operating loss and increased net interest expense. Interest expense rose to $1.9 million from $0.6 million, largely due to term loans.
- Ganetespib R&D spending rose 16% to $30.1 million as clinical development advanced; total R&D expense rose only 3% as spending declined in other programs.
- Quarterly 2011 financial data were corrected for weighted-average share-count errors affecting previously reported quarterly loss per share; reported net loss and cash flows were unchanged.
Outlook, risks, and unusual items
- Management expected ganetespib program costs to increase in 2012, while G&A was expected to remain near 2011 levels. The filing anticipated GALAXY trial interim results in Q2 2012 and further results during the second half of 2012; these were forward-looking expectations, not reported outcomes.
- The GALAXY Phase 2b/3 study tested ganetespib plus docetaxel against docetaxel alone in advanced non-small-cell lung cancer. Earlier biomarker and response findings were preliminary and involved small patient groups; they do not establish efficacy or approval.
- Roche’s termination returned CRACM program rights and related compounds to Synta, but removed the collaboration and its cost-sharing support. Synta could owe Roche a low-single-digit royalty on qualifying future product sales.
- The company had an accumulated deficit of $398.4 million and expected continued operating losses and cash use. Management warned that additional funding might be needed sooner than expected; financing could dilute shareholders or require licensing away rights.
- Other key risks included clinical-trial failure or delay, regulatory uncertainty, dependence on third-party manufacturers and clinical-research organizations, limited commercial capabilities, debt covenants and collateral provisions, competition, and intellectual-property challenges.
- Historical elesclomol trials were mostly negative or inconclusive, including the discontinued SYMMETRY Phase 3 trial. Current studies restricted enrollment based on LDH levels and used a new sodium-salt formulation, whose efficacy and safety remained uncertain.
Most important facts to verify
- Confirm the issuer and period: this is Synta’s FY2011 10-K, not Madrigal’s filing or a Q4-only report.
- Review the audited statements and notes for cash runway, debt balances, repayment terms, covenants, and the impact of the subsequent $33.0 million net equity financing.
- Check the status and results of the GALAXY, ALK-positive lung cancer, and breast cancer trials against the filing’s 2012 expectations.
- Assess the Roche termination’s effect on CRACM funding, rights, and potential royalty obligations.
- Review the corrected quarterly 2011 share counts and loss-per-share figures, and distinguish the one-time Roche revenue recognition from recurring operating revenue.